BioPharmSignal logoBioPharmSignal

Biotech News

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

SAB Biotherapeutics (SABS)SAB BiotherapeuticsCompany update

MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced presentations at the upcoming 62 nd

Related news

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

INMBINmune Bio2026-09-09 12:00 EST

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

BMYBMYBristol-Myers Squibb Company2026-08-29 15:00 EST

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

GRIGRI Bio2026-08-24 14:05 EST

GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026

IMMPImmutep Limited2026-07-24 12:00 EST

Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026

KNSAKiniksa2026-09-04 20:01 EST

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

KYTXKyverna Therapeutics2026-09-02 20:05 EST

Kyverna Therapeutics to Present at Upcoming Investor Conferences

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

View all latest news

SAB Biotherapeutics

Fully Human Polyclonal Antibodies SAB Biotherapeutics uses genetically engineered cattle to produce large quantities of fully human polyclonal antibodies. SAB-142 SAB-142 is a human anti-thymocyte immunoglobulin intended to preserve insulin-producing beta-cell function in newly diagnosed type 1 diabetes. SAFEGUARD The registrational...

Recent company news

SABSSAB Biotherapeutics2026-09-22 12:30 EST

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

SABSSAB Biotherapeutics2026-09-01 12:30 EST

SAB BIO to Participate in Upcoming Investor Conferences

SABSSAB Biotherapeutics2026-08-06 11:30 EST

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

SABSSAB Biotherapeutics2026-07-30 12:30 EST

SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

Stock data

Close
3.51 USD
Market cap
266.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States